Polybio Fall Symposium 2025
- Thread starter Jaybee00
- Start date
November 14th, two days from now.
Morgane Bomsel, who last year presented some striking differences in megakaryocyte and platelet viral persistence, is presenting again.
Morgane Bomsel, who last year presented some striking differences in megakaryocyte and platelet viral persistence, is presenting again.
Could be some worthwhile research amongst all this. The do seem to be largely focused on viral persistence.
I think I'll wait for papers to be published rather than trying to keep up from short talks. I assume the main value of this is expected to be for scientists to get a snapshot of each others work and ideas, and follow it up with private discussions.
I think I'll wait for papers to be published rather than trying to keep up from short talks. I assume the main value of this is expected to be for scientists to get a snapshot of each others work and ideas, and follow it up with private discussions.
Some notes on Morgane Bomsel's talk:
This is about patients with symptoms more than 6 months after acute COVID, and median 16 months after.
She showed a plot of SARS-CoV-2 detected in megakaryocytes which is the same as the one shown last year:
Around 30% of megakaryocytes in long COVID have SARS-CoV-2 RNA and spike:
From a sample of 17 LC patients and 6 recovered, most LC patients had platelets capable of infecting other cells, and none of the recovered did. I'm not sure if this is a random sample from their full cohort of > 100 LC.
This chart for spike in long COVID plasma is more filled in than last year's. She said they've studied more than 140 patients for this.
It's kind of strange because in the linked slide from last year, there were no points at 0 and the pink group (recovered controls) ranged from around 0.5 to 2 pg/mL, but in this slide they range from 0 to 0.8 pg/mL.
A topic she went into more this time was characterizing the platelets in LC. They were shifted away from mitochondrial respiration and more towards glycolysis:
And pathways affected when looking at gene expression in platelets:
This is about patients with symptoms more than 6 months after acute COVID, and median 16 months after.
She showed a plot of SARS-CoV-2 detected in megakaryocytes which is the same as the one shown last year:
Around 30% of megakaryocytes in long COVID have SARS-CoV-2 RNA and spike:
From a sample of 17 LC patients and 6 recovered, most LC patients had platelets capable of infecting other cells, and none of the recovered did. I'm not sure if this is a random sample from their full cohort of > 100 LC.
This chart for spike in long COVID plasma is more filled in than last year's. She said they've studied more than 140 patients for this.
It's kind of strange because in the linked slide from last year, there were no points at 0 and the pink group (recovered controls) ranged from around 0.5 to 2 pg/mL, but in this slide they range from 0 to 0.8 pg/mL.
A topic she went into more this time was characterizing the platelets in LC. They were shifted away from mitochondrial respiration and more towards glycolysis:
And pathways affected when looking at gene expression in platelets:
jnmaciuch
Senior Member (Voting Rights)
Was this a new slide? I'm trying to zoom in more to the flow plots and can't really see. But if this is real and not an artifact it could be really interesting
My mistake, I just looked at the video from last year, and it's the same plot. Timestamped link.